Navigation Links
Drug a New Treatment Option for Diabetic Eye Disease
Date:4/28/2010

Lucentis is first new therapy against diabetic macular edema in a quarter-century, experts say

WEDNESDAY, April 28 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.

Lucentis (ranibizumab) was originally developed to treat age-related macular degeneration. But researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.

The study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone. Results were similar after two years.

For 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.

The study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.

According to the U.S. National Eye Institute, DME occurs when fluid leaks into the center of the macula, the portion of the eye dedicated to sharp, straight-ahead vision. The condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.

The results of the new study "appear to be applicable to most people who have DME in the center of the macula with some vision loss, whether the person has type 1 or type 2 diabetes, is old or young, or is a woman or a man," Dr. Neil M. Bressler, chair of the DRCR Network and chief of the retina division, Wilmer Eye Institute, at Johns Hopkins University School of Medicine, said in a news release.

This is a "seminal" study," added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.

"First and most importantly, it provides patients an improved therapy for diabetic macular edema. Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment," Williams said.

The American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.

More information

The American Diabetes Association has more about diabetes-related eye complications.



-- Robert Preidt



SOURCE: American Academy of Ophthalmology, news release, April 27, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CBDM.T, The Market and Business Intelligence Company Reviews The Dry Eye Disease Treatment Market
2. Study examines global availability of treatment involving transplantation of blood stem cells
3. Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
4. Comparative-effectiveness study confirms new treatment for diabetic macular edema
5. Allergy Treatment from Absolute Health Provides Allergy Elimination as Opposed to Allergy Prevention
6. CureTogether Announces Online Autism Treatment Study
7. Nonmedical treatment may rapidly relieve severe IBS symptoms
8. New Varicose Vein Treatment Center Opens in Prescott, Arizona
9. Non-medical treatment may rapidly relieve severe IBS symptoms
10. Immune cells predict success of head and neck cancer treatment, U-M study finds
11. New report confirms fears of people living with HIV: Treatment rationing escalating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has raised ... of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of Iowa, ...
(Date:2/9/2016)... San Diego, California (PRWEB) , ... February 09, ... ... the launch of their new nationwide service to expand access to affordable ... over 30 million hard of hearing individuals in the United States. , “For ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and ... data vendors in the latest KLAS report, Population Health Management 2015: How Far Can ... market for population health management (PHM). The latest KLAS Report, leveraging over 200 ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, today reported its fourth quarter and full ... in vivo therapeutic genome editing," said Edward ... zinc finger nuclease (ZFN) technology leads the therapeutic ... core competencies necessary to move our ground-breaking genome ...
(Date:2/9/2016)... HAMILTON, Bermuda, Feb. 9, 2016  Axovant Sciences ... focused on the treatment of dementia, today announced ... address cognitive, behavioral and functional aspects of Lewy ... people in the U.S. Two out of the ... is expected to start later this quarter. In ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment & Forecast: ... global diagnostic ultrasound devices market was valued at US$ 5,381.1 million ... 2019 at a CAGR of 6.8% from 2015 to 2019. ... analyzed for six geographies of North America , ... Latin America , Middle-East and ...
Breaking Medicine Technology: